aTyr Pharma (LIFE) Misses Q1 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. WDC
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. FCNCA
9. TSCO
10. WCN

Go back to aTyr Pharma (LIFE) Misses Q1 EPS by 11c

aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update

May 9, 2022 4:00 PM EDT

Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May.

Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022.

FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD.

Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments.

Company to host... More